Parenti D - Search Results

1

Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.

Sikand VK, Halsey N, Krause PJ, Sood SK, Geller R, Van Hoecke C, Buscarino C, Parenti D; Pediatric Lyme Vaccine Study Group. Sikand VK, et al. Among authors: parenti d. Pediatrics. 2001 Jul;108(1):123-8. doi: 10.1542/peds.108.1.123. Pediatrics. 2001. PMID: 11433064 Clinical Trial.

2

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS. Steere AC, et al. Among authors: parenti dl. N Engl J Med. 1998 Jul 23;339(4):209-15. doi: 10.1056/NEJM199807233390401. N Engl J Med. 1998. PMID: 9673298 Free article. Clinical Trial.

3

Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.

Feder HM Jr, Beran J, Van Hoecke C, Abraham B, De Clercq N, Buscarino C, Parenti DL. Feder HM Jr, et al. Among authors: parenti dl. J Pediatr. 1999 Nov;135(5):575-9. doi: 10.1016/s0022-3476(99)70055-7. J Pediatr. 1999. PMID: 10547245 Clinical Trial.

4

Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.

Schoen RT, Sikand VK, Caldwell MC, Van Hoecke C, Gillet M, Buscarino C, Parenti DL. Schoen RT, et al. Among authors: parenti dl. Clin Ther. 2000 Mar;22(3):315-25. doi: 10.1016/S0149-2918(00)80035-1. Clin Ther. 2000. PMID: 10963286 Free article. Clinical Trial.

5

Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.

Van Hoecke C, Lebacq E, Beran J, Parenti D. Van Hoecke C, et al. Among authors: parenti d. Clin Infect Dis. 1999 Jun;28(6):1260-4. doi: 10.1086/514779. Clin Infect Dis. 1999. PMID: 10451163 Clinical Trial.

6

Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.

Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC. Smith RP, et al. Ann Intern Med. 2002 Mar 19;136(6):421-8. doi: 10.7326/0003-4819-136-6-200203190-00005. Ann Intern Med. 2002. PMID: 11900494 Clinical Trial.

7

Lyme disease vaccine.

Schofield DH, Parenti D. Schofield DH, et al. Among authors: parenti d. JAMA. 2000 Jan 12;283(2):199; author reply 200. doi: 10.1001/jama.283.2.199. JAMA. 2000. PMID: 10634331 No abstract available.

8

Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine.

Meurice F, Parenti D, Fu D, Krause DS. Meurice F, et al. Among authors: parenti d. Clin Infect Dis. 1997 Jul;25 Suppl 1:S71-5. doi: 10.1086/516167. Clin Infect Dis. 1997. PMID: 9233668

9

Lyme disease vaccine--LYMErix.

Parenti D. Parenti D. Conn Med. 1999 Sep;63(9):570. Conn Med. 1999. PMID: 10576966 No abstract available.

10

Outer surface protein A and arthritis in hamsters.

Parenti DL. Parenti DL. Infect Immun. 2000 Dec;68(12):7212-3. doi: 10.1128/IAI.68.12.7212-7213.2000. Infect Immun. 2000. PMID: 11203324 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters